Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 18, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 10.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 6 concluded trials, 83% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 18, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 15, 2027 | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Trial Milestone | Phase 2 |
| July 15, 2029 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia | Trial Milestone | Phase 3 |
Track LRMR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open LRMR in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.